Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 13, 2008

Silence Therapeutics and AstraZeneca Partner to Advance siRNA Drug Delivery Techniques

  • Silence Therapeutics and AstraZeneca are partnering to develop a range of approaches for the delivery of siRNA molecules. The deal builds on Silence Therapeutics' expertise in the delivery of siRNA molecules, in particular its experience with the functional systemic delivery of siRNA in vivo using its AtuPLEX technology.

    According to the firms, successful delivery of siRNA molecules to different tissue sites is critical to realize potential of siRNA to treat a broad range of diseases. Under the terms of the agreement, both Silence Therapeutics and AstraZeneca will be allowed to commercialize the delivery systems that they develop together.

    Silence Therapeutics will retain the right to sign further delivery deals to capture value from its current AtuPLEX delivery technology as well as any improvements to this technology that it generates either independently or as part of this collaboration.

    This new deal is independent of the parties' three-year collaboration signed in July 2007, whose aim is to develop novel siRNA therapeutics against specific targets exclusive to AstraZeneca.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »